Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays.

ABSTRACT:

Introduction

We aimed to evaluate clinical interpretation cutpoints for two plasma phosphorylated tau (p-tau)217 assays (ALZpath and Lumipulse) as predictors of amyloid status for implementation in clinical practice.

Methods

Clinical performance of plasma p-tau217 against amyloid positron emission tomography status was evaluated in participants with mild cognitive impairment or mild dementia (n = 427).

Results

Using a one-cutpoint approach (negative/positive), neither assay achieved ≥ 90% in both sensitivity and specificity. A two-cutpoint approach yielding 92% sensitivity and 96% specificity provided the desired balance of false positives and false negatives, while categorizing 20% and 39% of results as indeterminate for the Lumipulse and ALZpath assays, respectively

SUBMITTER: Figdore DJ 

PROVIDER: S-EPMC11497693 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature